Skip to main content

Navigation principale

  • About
  • Team
  • Portfolio
  • Strategy
  • ESG
  • Testimonials
  • News
  • Contact

Secondary Navigation

  • Fr
  • En

Actualités

You are here

  • Home
  • Actualités
ViroVet

First vaccine based on ViroVet PLLAV technology enters development

Post date
21/10/2020

ViroVet : Animal health company focused on combatting viral infections in livestock

LEUVEN, Belgium, October 21th, 2020 — ViroVet NV, a leading Belgian biopharmaceutical company active in the

Read more
Syndesi

Syndesi Therapeutics progresses development of SDI-118 for cognitive impairment and expands its series A financing

Post date
28/09/2020

Belgium – 28th September 2020 – Syndesi Therapeutics SA, a clinical stage biotechnology company developing novel modulators of the synaptic vesicle protein SV2A for the treatment of cognitive

Read more
Novadip

A child’s tibia healed with a 3D bone graft: World premiere of UCLouvain/Cliniques universitaires Saint-Luc

Post date
05/10/2020

Novadip Biosciences, spin-off of UCLouvain and Cliniques universitaires Saint-Luc (UCLouvain) have achieved a world first in bone reconstruction. Very promising results for the treatment of rare

Read more
Botalys

Recovering quickly and better from Covid-19: Walloon company Botalys tests a promising lead

Post date
10/09/2020

Even when cured, people with Covid-19 have significant sequelae: neurological or cardiovascular disorders, fatigue, loss of respiratory efficiency…

Ath, September 10, 2020 - Botalys has developed a

Read more
Promethera

Promethera® Announces Changes In Executive Leadership

Post date
02/09/2020
Promethera® Biosciences SA, a global innovator in cell-based medicines and liver diseases, based in Wallonia, Belgium, today announced that John Tchelingerian, PhD, has resigned from his position as
Read more
Novadip

Novadip Biosciences to Present at the LifeSci Partners Summer Symposium

Post date
29/07/2020

Mont-Saint Guibert, Belgium, 29 July, 2020: Novadip Biosciences ("Novadip" or "the Company"), a clinical-stage biopharmaceutical company leveraging its unique tissue regeneration technology platform

Read more
iTeos Therapeutics

iTeos Therapeutics Announces Pricing of Initial Public Offering

Post date
23/07/2020

CAMBRIDGE, Mass. and GOSSELIES, Belgium, July 23, 2020 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development

Read more
VIVES IUF

VIVES IUF: a new European inter-university fund of €32M to accelerate innovation

Post date
02/07/2020
  • The UCLouvain created, through its technology transfer office Sopartec, a new European university fund of €32m, VIVES Inter-University Fund
  • Its ambition? Accelerate the transformation of research
Read more
e-peas

E-PEAS Ready for Long-Term Growth After Raising a Further Euro 8 Million in Venture Capital

Post date
01/07/2020

1st July 2020 – Award-winning start-up e-peas continues to underline its reputation as the go-to supplier of advanced energy harvesting solutions, having just completed its latest funding round.  

Wi

Read more
Novadip

Novadip Biosciences to unveil its 3M3 Platform at BIO Digital 2020

Post date
04/06/2020

Unique 3M3 tissue regeneration technology platform generates multiple product candidates: autologous, off-the-shelf and miRNA/exosome

Mont-Saint Guibert, Belgium, 4 June, 2020: Novadip Biosciences (

Read more
Virovet

Seventure Partners joins ViroVet in series B funding

Post date
28/05/2020

Animal health company focused on combatting viral infections in livestock

LEUVEN, Belgium, May 28th, 2020 — ViroVet NV, a leading Belgian biopharmaceutical company active in the development of

Read more
Axinesis

To keep rehabilitation accessible during the lock-down, Axinesis is developing a remote rehabilitation solution

Post date
14/05/2020

 

  • Axinesis, the Walloon company specialized in medical devices for neurological rehabilitation, announces the CE mark for its new product, the REAtouch®.
  • It is a medical device for patients
Read more

Pagination

  • First page « First
  • Previous page ‹‹
  • Page 1
  • Page 2
  • Page 3
  • Current page 4
  • Page 5
  • Page 6
  • Next page ››
  • Last page Last »
 

VIVES Funds

VIVES Partners
Chemin du Stocquoy, 1
1300 Wavre
Belgium

Email
info@vivesfund.com
GSM
+32 472 206 355

Contact

Please note that VIVES only invests in companies located in Europe.
Maximum 5 files.
256 MB limit.
Allowed types: txt, rtf, pdf, doc, docx, odt, ppt, pptx, odp, xls, xlsx, ods.
Lire la politique générale de protection des données personnelles.

VIVES is a multi-sector technology fund that invests in spin-offs from UCLouvain and start-ups in Belgium and neighboring countries. The fund has the ability to invest at different stages of a company's development: seed, start-up and growth.

Menu Pied de page

  • Privacy policy & cookies
  • Terms & conditions
  • © 2025 All rights reserved.
  • Website by Visible